When only RCTs of men with baseline total testosterone values 326 It is unlikely that these changes represent clinically meaningful differences. A similar meta-analysis of only RCTs demonstrated no changes in total cholesterol or triglycerides in men who were on testosterone as compared to those on placebo. Compared to placebo, no significant changes were noted with testosterone therapy, including when the data were evaluated as a continuous or dichotomous (≥4 point change) variable. There are conflicting results in the literature as to whether testosterone therapy has a significant impact on these symptoms. Men who seek medical care for possible testosterone therapy often present with non-specific symptoms, such as low energy and fatigue, which can be manifestations of other conditions, such as chronic stress, chronic fatigue, and depression. Patients should be informed that testosterone therapy may result in improvements in erectile function, low sex drive, anemia, bone mineral density, lean body mass, and/or depressive symptoms. Clinicians should inform testosterone deficient patients that low testosterone is a risk factor for cardiovascular disease. Clinicians should use a total testosterone level below 300 ng/dL as a reasonable cut-off in support of the diagnosis of low testosterone. In our case series of eight patients, hormonal treatment provided satisfactory results overall with no apparent side effects. Lastly, the monitoring process during treatment, possible side effects, and the future need for exogenous T supplementation in low-level T males after sperm retrieval must be considered. There does appear to be a trend towards lower total testosterone and a diagnosis of ED. There are inherent challenges in testosterone measurement due to the health status of patients at the time of testing, circadian rhythms in testosterone production, intra-individual variability, and inconsistencies in the assays themselves. Given that the direct method for free testosterone measurement is also time-consuming and labor intensive, calculation derived free testosterone measurement is more commonly used, however there is considerable variation in total testosterone assays as well as the clinical conditions that affect serum albumin and SHBG, all of which impact this measurement. The Panel recommends that clinicians use the same laboratory with the same method/instrumentation for serial total testosterone measurement. There is a great deal of variability across studies with respect to the forms of testosterone measured (total versus free), the assays utilized to measure testosterone, the time of day when the sample is obtained, and the number of testosterone measurements taken. As an example, a total testosterone value of 250 ng/dL may be considered low based on the current guideline but be marked within the normal range by the laboratory. In the event that patients do not experience symptomatic relief after reaching the specified target testosterone levels or remain testosterone deficient in the setting of symptom/sign improvement, testosterone therapy should be stopped. Conversely, a population-based retrospective case-control study utilizing a UK clinical database of 19,215 patients with confirmed VTE showed that there was increased risk of VTE in the first 6 months of testosterone therapy. Prostate cancer patients on testosterone therapy should have their PSA levels monitored on the same schedule as men without testosterone deficiency; however, clinicians may choose to increase the frequency of testing. In conclusion, HCG injections offer several benefits for men’s health, including increased testosterone levels, fertility enhancement, and potential improvements in weight loss and muscle gain. Human Chorionic Gonadotropin (HCG) injections are commonly used in men to treat low testosterone levels, improve fertility, and aid when you’re trying to lose weight. By increasing testosterone levels, trigger shots can potentially provide several benefits for men’s health.
